Acadia Pharmaceuticals Inc
ACAD· Nasdaq
ACADAcadia Pharmaceuticals Inc
Released Feb 28, 2022, after the close
10-K filed Mar 1, 2022, 60 days after period end · 0000950170-22-002392
| Metric | Q4 2021 | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $130.76M | $121.01M | $98.33M | $59.57M |
| Net Income | -$43.09M | -$66.76M | -$53.04M | -$65.49M |
Acadia Pharmaceuticals Inc · CIK 1070494 · Engraved from SEC EDGAR
| EPS Diluted | -$0.27 | — | -$0.34 | -$0.50 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
